An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Thyroid Cancer
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment options for thyroid cancer are described in Table 1.
Sources: Table 1
| Type of Thyroid Cancer | Disease Status | Treatment Options | |
|---|---|---|---|
| T = primary tumor; N = regional lymph node; M = distant metastases; EBRT = external-beam radiation therapy; RAI = radioactive iodine. | |||
| Papillary and follicular | Localized/regional | Surgery | |
| –Total thyroidectomy | |||
| –Lobectomy | |||
| RAI therapy | |||
| Thyroid-suppression therapy | |||
| EBRT | |||
| Papillary and follicular | Metastatic | Iodine-sensitive: | |
| RAI therapy | |||
| Thyroid-suppression therapy | |||
| Iodine-resistant: | |||
| Thyroid-suppression therapy | |||
| Targeted therapy | |||
| Surgery | |||
| EBRT | |||
| Chemotherapy (under clinical evaluation) | |||
| Clinical trials | |||
| Recurrent papillary and follicular thyroid cancer | Surgery with or without postoperative RAI therapy | ||
| Targeted therapy | |||
| EBRT | |||
| Chemotherapy | |||
| Clinical trials | |||
| Medullary thyroid cancer | Localized disease | Total thyroidectomy | |
| EBRT | |||
| Locally advanced and metastatic disease | Targeted therapy | ||
| Palliative chemotherapy | |||
| Anaplastic thyroid cancer | Surgery | ||
| EBRT | |||
| Systemic therapy | |||
Sources: Surgery · –Total thyroidectomy · –Lobectomy · RAI therapy · Thyroid-suppression therapy · EBRT · RAI therapy · Thyroid-suppression therapy · Thyroid-suppression therapy · Targeted therapy · Surgery · EBRT · Chemotherapy · Clinical trials · Surgery with or without postoperative RAI therapy · Targeted therapy · EBRT · Chemotherapy · Clinical trials · Total thyroidectomy · EBRT · Targeted therapy · Palliative chemotherapy · Surgery · EBRT · Systemic therapy
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Surgery is the therapy of choice for all primary lesions. Surgical options include total thyroidectomy or lobectomy. The choice of procedure is influenced mainly by the age of the patient and the size of the nodule. For patients with early-stage disease, survival rates are similar when comparing the two procedures; however, the rates of surgical complications and local recurrences are different.[2-8]
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment options for localized/regional papillary and follicular thyroid cancer include:
Surgery.
Sources: Surgery
Lobectomy.
Sources: Lobectomy
Radioactive iodine (RAI) therapy.
Sources: Radioactive iodine (RAI) therapy
Thyroid-suppression therapy.
Sources: Thyroid-suppression therapy
External-beam radiation therapy (EBRT).
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
The objective of surgery is to completely remove the primary tumor, while minimizing treatment-related morbidity, and to guide postoperative treatment with RAI. The goal of RAI is to ablate the remnant thyroid tissue to improve the specificity of thyroglobulin assays, which allows the detection of persistent disease by follow-up whole-body scanning. For patients undergoing RAI, removal of all normal thyroid tissue is an important surgical objective. Additionally, for accurate long-term surveillance, RAI whole-body scanning and measurement of serum thyroglobulin are affected by residual, normal thyroid tissue. In these situations, near total or total thyroidectomy is required. This approach facilitates follow-up thyroid scanning.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Total thyroidectomy is often used because of the high incidence of multicentric involvement of both lobes of the gland and the possibility of dedifferentiation of any residual tumor to the anaplastic cell type.
Evidence (total thyroidectomy):
An analysis of the National Cancer Data Base (NCDB) registry identified 52,173 patients who underwent surgery for papillary thyroid cancer. Of these individuals, 43,227 (82.9%) underwent total thyroidectomy, and 8,946 (17.1%) underwent lobectomy.[9][Level of evidence C1]
Sources: 9 · Level of evidence C1
An analysis of the National Cancer Data Base (NCDB) registry identified 52,173 patients who underwent surgery for papillary thyroid cancer. Of these individuals, 43,227 (82.9%) underwent total thyroidectomy, and 8,946 (17.1%) underwent lobectomy.[9][Level of evidence C1]
For a papillary thyroid cancer tumor that measured less than 1 cm, the extent of surgery did not impact recurrence (P = .24) or survival (P = .83).
For tumors that measured 1 cm or larger, lobectomy resulted in higher risk of recurrence (P = .04) and death (P = .009).
To minimize the influence of larger tumors, 1-cm to 2-cm lesions were examined separately. Lobectomy resulted in a higher risk of recurrence (P = .04) and death (P = .04).
For patients with papillary thyroid cancer tumors that measured 1 cm or larger, total thyroidectomy resulted in lower recurrence rates and improved survival compared with lobectomy.
In a pattern-of-care study that used the NCDB registry from 1985 to 2003, 57,243 patients with papillary thyroid cancer whose tumors measured 1 cm or larger underwent total thyroidectomy or lobectomy. Trends in the extent of surgery were examined for patients with papillary thyroid cancer over two decades. Logistic regression was used to identify factors that predicted the use of total thyroidectomy compared with lobectomy.[10][Level of evidence C1]
Sources: 10 · Level of evidence C1
In a pattern-of-care study that used the NCDB registry from 1985 to 2003, 57,243 patients with papillary thyroid cancer whose tumors measured 1 cm or larger underwent total thyroidectomy or lobectomy. Trends in the extent of surgery were examined for patients with papillary thyroid cancer over two decades. Logistic regression was used to identify factors that predicted the use of total thyroidectomy compared with lobectomy.[10][Level of evidence C1]
Use of total thyroidectomy increased from 70.8% in 1985 to 90.4% in 2003 (P < .0001).
Patients treated at high-volume medical facilities or academic centers were more likely to undergo total thyroidectomy than were patients examined at low-volume medical facilities or community hospitals (P < .0001).
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Thyroid lobectomy alone may be sufficient treatment for small (<1 cm), low-risk, unifocal, intrathyroidal papillary carcinomas in the absence of previous head and neck irradiation or radiologically or clinically involved cervical nodal metastases. This procedure is associated with a lower incidence of complications, but approximately 5% to 10% of patients will have a recurrence in the thyroid after a lobectomy.[11]
Sources: 11
Abnormal regional lymph nodes are biopsied at the time of surgery. Recognized involved nodes are removed at initial surgery, but selective node removal can be performed, and radical neck dissection is usually not required. This results in a decreased recurrence rate but has not been shown to improve survival. Follicular thyroid cancer commonly metastasizes to lungs and bone. When a remnant lobe remains, use of iodine I 131 as ablative therapy is compromised because the radioiodine will be preferentially taken up by the remnant normal tissue rather than by the tumor.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Studies have shown that a postoperative course of therapeutic (ablative) doses of radioiodine 131I results in a decreased recurrence rate among high-risk patients with papillary and follicular carcinomas.[5] RAI may be given in addition to exogenous thyroid hormone but is not considered routine.[12] RAI treatment is optimal after total thyroidectomy with minimal thyroid remnant. With a large thyroid remnant, a low thyroglobulin level cannot be achieved, which increases the chance of requiring multiple doses of RAI.
Consideration of RAI for remnant ablation is based on the following pathological risk features:
The size of the primary tumor.
The presence of lymphovascular invasion.
Capsule invasion.
The number of involved lymph nodes.
RAI may be given with one of two methods of thyroid-stimulating hormone (TSH/thyrotropin) stimulation:
Withdrawal of thyroid hormone.
Administration of recombinant human thyrotropin (rhTSH).
Administered rhTSH maintains quality of life and reduces the radiation dose delivered to the body compared with thyroid hormone withdrawal.[13] Patients presenting with papillary thyroid microcarcinomas (tumors <10 mm), which are considered to be very low risk, have an excellent prognosis when treated surgically. Additional therapy with 131I would not be expected to improve the prognosis.[14]
The role of RAI in low-risk patients is not clear because disease-free survival (DFS) or overall survival (OS) benefits have not been demonstrated.
Evidence (surgery with or without RAI):
One study reviewed 1,298 patients with low-risk disease from the French Thyroid Cancer Registry.[15] Patients were identified as having low-risk papillary or follicular cancer as defined by the following American Thyroid Association and European Thyroid Association criteria:
Sources: 15
One study reviewed 1,298 patients with low-risk disease from the French Thyroid Cancer Registry.[15] Patients were identified as having low-risk papillary or follicular cancer as defined by the following American Thyroid Association and European Thyroid Association criteria:
Complete tumor resection.
Multifocal tumors 1 cm or smaller confined to the thyroid.
Tumors larger than 1 cm but no larger than 4 cm confined to the thyroid.
No lymph node involvement or distant metastatic disease.
Of the 1,298 patients, 911 patients received RAI after surgery, and 387 patients did not receive RAI after surgery. The follow-up period was 10.3 years.
In multivariate analyses, there were no differences in OS (P = .243) or DFS (P = .2659), according to RAI use.[15]
Sources: 15
Long-term complications of RAI with 131I include:
Second malignancies.
Sialadenitis.
Lacrimal and salivary gland dysfunction.
Options for decreasing radiation exposure in patients with low-risk thyroid cancer have been explored. These options have included reducing the amount of RAI in each dose and giving RAI in combination with rhTSH injections.
Evidence (thyroid hormone withdrawal or use of rhTSH with 131I):
A phase III, randomized, noninferiority study included patients with low-risk thyroid cancer. The study compared two thyrotropin-stimulation methods (thyroid hormone withdrawal or use of rhTSH) and two 131I doses (1.1 GBq [30 mCi] and 3.7 GBq [100 mCi]), using a 2 × 2 factorial design.[16][Level of evidence C1]
Sources: 16 · Level of evidence C1
A phase III, randomized, noninferiority study included patients with low-risk thyroid cancer. The study compared two thyrotropin-stimulation methods (thyroid hormone withdrawal or use of rhTSH) and two 131I doses (1.1 GBq [30 mCi] and 3.7 GBq [100 mCi]), using a 2 × 2 factorial design.[16][Level of evidence C1]
Thyroid ablation rates were equivalent between high- and low-dose 131I at 6 to 10 months after administration of 131I.
Patients with more advanced T stage (T1–T3, N0–1) and with less than a total thyroidectomy were included with a lower overall ablation rate of 85%.
Another phase III, randomized, noninferiority study of patients with low-risk thyroid cancer compared two thyrotropin-stimulation methods (thyroid hormone withdrawal or use of rhTSH) and two 131I doses (1.1 GBq [30 mCi] and 3.7 GBq [100 mCi]), using a 2 × 2 factorial design. The inclusion criteria consisted of a low-risk, homogeneous cohort. All of the patients underwent total thyroidectomy and had pathological TNM stage pT1 (≤1 cm) and N1 or NX, pT1 (>1–2 cm) and any N, or pT2, N0 without thyroid capsule extension/distant metastases.[17][Level of evidence C1]
Sources: 17 · Level of evidence C1
Another phase III, randomized, noninferiority study of patients with low-risk thyroid cancer compared two thyrotropin-stimulation methods (thyroid hormone withdrawal or use of rhTSH) and two 131I doses (1.1 GBq [30 mCi] and 3.7 GBq [100 mCi]), using a 2 × 2 factorial design. The inclusion criteria consisted of a low-risk, homogeneous cohort. All of the patients underwent total thyroidectomy and had pathological TNM stage pT1 (≤1 cm) and N1 or NX, pT1 (>1–2 cm) and any N, or pT2, N0 without thyroid capsule extension/distant metastases.[17][Level of evidence C1]
Thyroid ablation rates were equivalent between high- and low-dose 131I at 6 to 10 months after administration of 131I.
Complete thyroid ablation rate was 92%.
Patients who underwent thyroid hormone withdrawal had more symptoms of hypothyroidism associated with deterioration in quality of life than the patients who received rhTSH.
Neither study assessed the effect of low-dose RAI on long-term recurrences or survival. The studies also did not address whether RAI could be safely omitted in specific low-risk groups.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
After thyroid surgery, all patients, except those undergoing lobectomies, require thyroid hormone replacement therapy. For patients who have undergone thyroidectomy, supratherapeutic doses of thyroid hormone are routinely given to suppress TSH levels. The degree of TSH suppression recommended depends on the risk of recurrence and the comorbidities of the patient. Studies have suggested that TSH suppression improves progression-free survival (PFS), but there is no definitive evidence that it improves OS.[18,19]
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
EBRT is typically reserved for palliative treatment of unresectable or metastatic papillary or follicular thyroid cancer. In some cases, it may be appropriate to give EBRT in the adjuvant setting if there is confirmed or suspected microscopic residual disease that is confirmed or suspected to be refractory to RAI. There are no randomized trials to guide the selection of patients who might benefit from treatment with EBRT. The decision to use EBRT is based on retrospective data and clinical judgment.[20]
Sources: 20
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Total thyroidectomy is still recommended as the initial treatment for metastatic papillary or follicular thyroid cancer. RAI is the second treatment and is given to ablate the remnant thyroid and treat the metastatic disease. If a thyroidectomy is not done, then RAI is not a treatment option for the patient. The most common sites of distant metastases are the lungs and bones. Treatment of distant metastases is usually not curative but may produce significant palliation. Genomic testing to identify actionable variants like RET and NTRK gene fusions should be considered for patients with advanced progressive disease. Treatment options for iodine-sensitive and iodine-resistant metastatic papillary and follicular thyroid cancer are described below.
Treatment options for iodine-sensitive thyroid cancer
Treatment options for iodine-sensitive thyroid cancer include:
RAI therapy. Metastases that demonstrate uptake of this isotope may be ablated by therapeutic doses of 131I.
Thyroid-suppression therapy.
Treatment options for iodine-resistant thyroid cancer
Treatment options for iodine-resistant thyroid cancer include:
Thyroid-suppression therapy.
Sources: Thyroid-suppression therapy
Targeted therapy.
Sources: Targeted therapy
Surgery.
Sources: Surgery
EBRT.
Sources: EBRT
Chemotherapy (under clinical evaluation).
Sources: Chemotherapy
Clinical trials.
Sources: Clinical trials
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
TSH suppression with thyroxine is effective in many lesions that are not sensitive to 131I.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Sorafenib is an orally active multitargeted tyrosine kinase inhibitor.
Evidence (sorafenib):
A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated the activity of sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] The trial included 417 patients with locally advanced or metastatic RAI−refractory thyroid cancer (papillary, follicular [including Hürthle cell], and poorly differentiated, not anaplastic tumors, defined as beyond well-differentiated tumors or those well-differentiated tumors that become resistant to radioiodine treatment) whose disease had progressed within the past 14 months. Patients were randomly assigned to receive either sorafenib (400 mg twice a day) or placebo. Patients who received previous chemotherapy, thalidomide, or targeted therapy were excluded.[21][Level of evidence B1]
Sources: DECISION · 21 · 21 · Level of evidence B1
A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated the activity of sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] The trial included 417 patients with locally advanced or metastatic RAI−refractory thyroid cancer (papillary, follicular [including Hürthle cell], and poorly differentiated, not anaplastic tumors, defined as beyond well-differentiated tumors or those well-differentiated tumors that become resistant to radioiodine treatment) whose disease had progressed within the past 14 months. Patients were randomly assigned to receive either sorafenib (400 mg twice a day) or placebo. Patients who received previous chemotherapy, thalidomide, or targeted therapy were excluded.[21][Level of evidence B1]
The median PFS was 10.8 months in the sorafenib group and 5.8 months in the placebo group (hazard ratio [HR] 0.59; 95% confidence interval [CI], 0.45–0.76; P < .0001).
OS was not significantly improved (HR, 0.80; 95% CI, 0.54–1.19; one-sided P = .14), but the median OS had not been reached at the time of primary analysis data cutoff, and crossover was allowed.
The objective response rate (all partial responses) was 12.2% in the sorafenib group and 0.5% in the placebo group.
Median time-to-progression was 11.1 months in the sorafenib group and 5.7 months in the placebo group (HR, 0.56; 95% CI, 0.43–0.72; P < .001).
Adverse events occurred in 98.6% of patients treated with sorafenib and 87.6% of patients treated with placebo. The most common adverse events in the sorafenib group were hand-foot skin reactions (76.3%), diarrhea (68.6%), alopecia (67.1%), and rash or desquamation (50.2%). Most events were grade 1 or 2. Seven squamous cell carcinomas of the skin occurred in the sorafenib group.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Lenvatinib is an orally active, multitargeted tyrosine kinase inhibitor.
Evidence (lenvatinib):
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1]
Sources: SELECT · 22 · 22 · Level of evidence B1
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1]
The median PFS was 18.3 months in the lenvatinib group and 3.6 months in the placebo group (HRprogression or death, 0.21; 99% CI, 0.14–0.31; P < .001). A PFS difference was observed in patients with all histological types of thyroid cancer enrolled in this trial.
There was no significant difference in OS between the two groups (HR death, 0.73; 95% CI, 0.50–1.07; P = .10), even with the crossover design of the study.
The objective response rate was 64.8% in the lenvatinib group versus 1.5% in the placebo group (odds ratio [OR], 28.87; 95% CI, 12.46–66.86; P < .001).
Treatment-related adverse events (all grades) occurred in 97.3% of patients in the lenvatinib group and 59.5% of patients in the placebo group.
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1] › Treatment-related adverse events (all grades) occurred in 97.3% of patients in the lenvatinib group and 59.5% of patients in the placebo group.
Grade 3 or higher adverse events were observed in 75.9% of patients who received lenvatinib and 9.9% of patients who received placebo.
The most common adverse events in the lenvatinib group were hypertension (67.8%), diarrhea (59.4%), fatigue (59%), decreased appetite (50.2%), decreased weight (46.4%), and nausea (41%).
Adverse events led to discontinuation of the study drug in 14.2% of patients who received lenvatinib and 2.3% of patients who received placebo.
In the lenvatinib group, 6 of 20 deaths occurring during the treatment period were considered drug related.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Resection of limited metastases, especially symptomatic metastases, should be considered when the tumor has no uptake of 131I.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
EBRT is considered for patients with localized lesions that are unresponsive to 131I.[23]
Sources: 23
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Patients with radioiodine-refractory papillary or follicular thyroid cancer can consider participating in clinical trials that evaluate new treatment approaches. Oral inhibitors targeting specific single nucleotide variants are under clinical evaluation, as are new immunotherapy approaches.[27-29][Level of evidence B4]
Sources: 27 · 29 · Level of evidence B4
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Approximately 10% to 30% of patients thought to be disease free after initial treatment develop recurrence and/or metastases. Of these patients, approximately 80% develop recurrence with disease in the neck alone, and 20% develop recurrence with distant metastases. The lungs are the most common site of distant metastasis. In a single series of 289 patients who developed recurrences after initial surgery, 16% died of cancer at a median time of 5 years after recurrence.[5]
Sources: 5
The prognosis for patients with clinically detectable recurrences is generally poor, regardless of cell type.[30] Patients with local or regional tumor recurrence detected only by 131I scan have a better prognosis.[31]
The selection of further treatment depends on many factors, including:
Cell type.
Uptake of 131I.
Previous treatment.
Site of recurrence.
Individual patient considerations.
Presence of an activating RET or NTRK gene fusion.
Patients treated for differentiated thyroid cancer are monitored carefully with physical examinations, serum quantitative thyroglobulin levels, and radiological studies based on individual risk for recurrent disease.[32]
Sources: 32
Treatment options for recurrent papillary and follicular thyroid cancer
Treatment options for recurrent papillary and follicular thyroid cancer include:
Surgery with or without postoperative RAI.
Targeted therapy.
Sources: Targeted therapy
RET kinase inhibitors.
Sources: RET kinase inhibitors
NTRK inhibitors.
Sources: NTRK inhibitors
EBRT.
Sources: EBRT
Chemotherapy.
Sources: Chemotherapy
Clinical trials.
Sources: Clinical trials
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Surgery with or without 131I ablation can be useful in controlling local recurrences, regional node metastases, or occasionally, metastases at other localized sites.[33] Approximately 50% of the patients who undergo surgery for recurrent tumors can be rendered free of disease with a second operation.[30] Local and regional recurrences detected by 131I scan and not clinically apparent can be treated with 131I ablation and have an excellent prognosis.[34]
Up to 25% of recurrences and metastases from well-differentiated thyroid cancer may not show 131I uptake. For these patients, other standard imaging techniques such as ultrasonography, computed tomography, magnetic resonance imaging, and positron emission tomography scans may detect recurrent or metastatic disease.
Patients unresponsive to 131I should consider enrolling in clinical trials testing new approaches to treating this disease.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Sorafenib is an orally active, multitargeted tyrosine kinase inhibitor. The U.S. Food and Drug Administration (FDA) approved sorafenib as a treatment option when recurrent disease does not concentrate 131I or disease recurs after 131I ablation.
Evidence (sorafenib):
A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] This trial included 417 patients with locally advanced or metastatic RAI-refractory thyroid cancer (papillary, follicular [including Hürthle cell], and poorly differentiated tumors) whose disease had progressed within the past 14 months. Patients were randomly assigned to receive either sorafenib (400 mg twice a day) or placebo. Patients who received previous chemotherapy, thalidomide, or targeted therapy were excluded.[21][Level of evidence B1]
Sources: DECISION · 21 · 21 · Level of evidence B1
A phase III, randomized, double-blind, placebo-controlled study (DECISION [NCT00984282]) evaluated sorafenib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[21] This trial included 417 patients with locally advanced or metastatic RAI-refractory thyroid cancer (papillary, follicular [including Hürthle cell], and poorly differentiated tumors) whose disease had progressed within the past 14 months. Patients were randomly assigned to receive either sorafenib (400 mg twice a day) or placebo. Patients who received previous chemotherapy, thalidomide, or targeted therapy were excluded.[21][Level of evidence B1]
The median PFS was 10.8 months in the sorafenib group and 5.8 months in the placebo group (HR, 0.59; 95% CI, 0.45–0.76; P < .001).
OS was not significantly improved (HR, 0.80; 95% CI, 0.54–1.19; one-sided P = .14), but the median OS had not been reached at the time of primary analysis data cutoff, and crossover was allowed.
Objective response rates (all partial responses) were 12.2% in the sorafenib group and 0.5% in the placebo group.
Median time-to-progression was 11.1 months in the sorafenib group and 5.7 months in the placebo group (HR, 0.56; 95% CI, 0.43–0.72; P < .001).
Adverse events occurred in 98.6% of patients treated with sorafenib and 87.6% of patients treated with placebo. The most common adverse events in the sorafenib group were hand-foot skin reactions (76.3%), diarrhea (68.6%), alopecia (67.1%), and rash or desquamation (50.2%). Most events were grade 1 or 2. Seven squamous cell carcinomas of the skin occurred in the sorafenib group.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Lenvatinib is an orally active, multitargeted tyrosine kinase inhibitor.
Evidence (lenvatinib):
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1]
Sources: SELECT · 22 · 22 · Level of evidence B1
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1]
The median PFS in the lenvatinib group was 18.3 months versus 3.6 months in the placebo group (HRprogression or death, 0.21; 99% CI, 0.14–0.31; P < .001). A PFS difference was observed in patients with all histological types of thyroid cancer enrolled in this trial.
There was no significant difference in OS between the two groups (HRdeath, 0.73; 95% CI, 0.50–1.07; P = .10), even with the crossover design of the study.
The objective response rate was 64.8% in the lenvatinib group and 1.5% in the placebo group (OR, 28.87; 95% CI, 12.46–66.86; P < .001).
Treatment-related adverse events (all grades) occurred in 97.3% of patients in the lenvatinib group and 59.5% of patients in the placebo group.
A phase III, randomized, double-blind, placebo-controlled study (SELECT [NCT01321554]) evaluated the activity of lenvatinib in patients with progressive, iodine-refractory, differentiated thyroid cancer.[22] In this trial, 261 patients were randomly assigned to receive lenvatinib (24 mg every day), and 131 patients were randomly assigned to receive placebo. Eligible patients had differentiated thyroid cancer (including papillary, follicular, poorly differentiated, and Hürthle cell carcinomas), RAI-refractory disease, and evidence of radiological progression within the previous 13 months. At disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was PFS, while the secondary end points were OS, response rate, and safety.[22][Level of evidence B1] › Treatment-related adverse events (all grades) occurred in 97.3% of patients in the lenvatinib group and 59.5% of patients in the placebo group.
Grade 3 or higher adverse events were observed in 75.9% of patients who received lenvatinib and 9.9% of patients who received placebo.
The most frequent adverse events in the lenvatinib group were hypertension (67.8%), diarrhea (59.4%), fatigue (59%), decreased appetite (50.2%), decreased weight (46.4%), and nausea (41%).
Adverse events led to discontinuation of the study drug in 14.2% of patients who received lenvatinib and 2.3% of patients who received placebo.
In the lenvatinib group, 6 of 20 deaths occurring during the treatment period were considered drug related.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Cabozantinib is an orally bioavailable tyrosine kinase inhibitor of c-MET and vascular endothelial growth factor receptor-2 (VEGFR-2).
Evidence (cabozantinib):
A phase III, randomized, double blind, placebo-controlled study (COSMIC-311 [NCT03690388]) was conducted to evaluate the efficacy of cabozantinib in patients aged 16 years and older with RAI-refractory differentiated thyroid cancer. Objective response rate was the primary end point in the first 100 randomly assigned patients (the objective response rate intention-to-treat [OITT] population), and PFS was the primary end point in all randomly assigned patients (the intention-to-treat [ITT] population).[35]
Sources: COSMIC-311 · 35
A phase III, randomized, double blind, placebo-controlled study (COSMIC-311 [NCT03690388]) was conducted to evaluate the efficacy of cabozantinib in patients aged 16 years and older with RAI-refractory differentiated thyroid cancer. Objective response rate was the primary end point in the first 100 randomly assigned patients (the objective response rate intention-to-treat [OITT] population), and PFS was the primary end point in all randomly assigned patients (the intention-to-treat [ITT] population).[35]
Of 187 patients, 63% had received previous therapy with lenvatinib, 60% had received previous therapy with sorafenib, and 24% had received previous therapy with both lenvatinib and sorafenib. Most patients (76%) had experienced disease progression while receiving sorafenib or lenvatinib.
In the OITT population, 15% of patients (99% CI, 5.8%–29.3%) in the cabozantinib group had a confirmed partial response, and median duration of response had not been reached at the data cutoff.
In the ITT population, after a median follow-up of 6.2 months, patients who received cabozantinib showed significant improvement in PFS compared with patients who received placebo (median not reached [96% CI, 5.7–not estimable (NE)] vs. 1.9 months [1.8–3.6]) (HR, 0.22; 96% CI, 0.13–0.36; P < .0001). Median OS was not reached in either ITT group (95% CI, NE–NE) (HR, 0.54; 95% CI, 0.27–1.11). The 6-month OS rate was 85% (95% CI, 75%–91%) in the cabozantinib group and 73% (58.4%–83.7%) in the placebo group.
Grade 3 to 4 treatment-related adverse events occurred in 57% of patients who received cabozantinib and 26% of patients who received placebo, and included palmar-plantar erythrodysesthesia (10%), hypertension (11%), fatigue (8%), diarrhea (7%), and hypocalcemia (7%). Serious treatment-related adverse events occurred in 20 of 125 patients (16%) in the cabozantinib group and 1 of 62 patients (2%) in the placebo group. There were no treatment-related deaths.
In 2021, the FDA reviewed a new drug application for the use of cabozantinib in patients aged 12 years and older with differentiated thyroid cancer because there are no standard-of-care treatments for this population after anti-VEGFR therapy, such as lenvatinib or sorafenib.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Selpercatinib is an orally active, highly selective, small-molecule RET kinase inhibitor.
Evidence (selpercatinib):
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor with an activating RET pathogenic variant. The primary end point was an objective response (complete response or partial response). Patients with RET fusion–positive thyroid cancer had radioiodine-refractory disease and received at least one previous systemic therapy other than radioiodine. Nineteen patients with RET fusion–positive thyroid cancer were enrolled; 13 patients had papillary thyroid cancer, 3 had poorly differentiated thyroid cancer, 1 had anaplastic thyroid cancer, and 1 had Hürthle cell thyroid cancer. Ninety-five percent of patients with RET fusion–positive thyroid cancer received the phase II dose of 160 mg twice daily.[36]
Sources: LIBRETTO-001 · 36
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor with an activating RET pathogenic variant. The primary end point was an objective response (complete response or partial response). Patients with RET fusion–positive thyroid cancer had radioiodine-refractory disease and received at least one previous systemic therapy other than radioiodine. Nineteen patients with RET fusion–positive thyroid cancer were enrolled; 13 patients had papillary thyroid cancer, 3 had poorly differentiated thyroid cancer, 1 had anaplastic thyroid cancer, and 1 had Hürthle cell thyroid cancer. Ninety-five percent of patients with RET fusion–positive thyroid cancer received the phase II dose of 160 mg twice daily.[36]
The objective response rate was 79% (95% CI, 54%−94%).[36][Level of evidence C2]
Sources: 36 · Level of evidence C2
At 1 year, 71% of responses were ongoing (95% CI, 39%−88%) and 64% of patients were progression-free.
Treatment-related adverse events (any grade) occurred in 94% of patients.
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor with an activating RET pathogenic variant. The primary end point was an objective response (complete response or partial response). Patients with RET fusion–positive thyroid cancer had radioiodine-refractory disease and received at least one previous systemic therapy other than radioiodine. Nineteen patients with RET fusion–positive thyroid cancer were enrolled; 13 patients had papillary thyroid cancer, 3 had poorly differentiated thyroid cancer, 1 had anaplastic thyroid cancer, and 1 had Hürthle cell thyroid cancer. Ninety-five percent of patients with RET fusion–positive thyroid cancer received the phase II dose of 160 mg twice daily.[36] › Treatment-related adverse events (any grade) occurred in 94% of patients.
Grade 3 adverse events were observed in 28% of patients, and grade 4 adverse events were observed in 2% of patients.
The most frequent adverse events were dry mouth (46%), hypertension (43%), diarrhea (38%), fatigue (38%), increased aspartate aminotransferase (AST) level (35%), nausea (35%), and constipation (35%).
Thirty percent of patients had dose reductions because of treatment-related adverse events, and 2% of patients discontinued the drug because of adverse events.
A phase III randomized trial (NCT04211337) compared first-line selpercatinib with physician’s choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease within the 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was PFS, assessed by blinded independent central review. Patients in the control group with disease progression were permitted to cross over to the selpercatinib group. Treatment failure–free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if PFS was significant. Other secondary end points included overall response and safety.[37]
Sources: NCT04211337 · 37
A phase III randomized trial (NCT04211337) compared first-line selpercatinib with physician’s choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease within the 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was PFS, assessed by blinded independent central review. Patients in the control group with disease progression were permitted to cross over to the selpercatinib group. Treatment failure–free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if PFS was significant. Other secondary end points included overall response and safety.[37]
At a median follow-up of 12 months, the median PFS was not reached in the selpercatinib group and was 16.8 months in the control group (95% CI, 12.2–25.1) (HRdisease progression or death, 0.28; 95% CI, 0.16–0.48; P < .001).[37][Level of evidence B1]
Sources: 37 · Level of evidence B1
The 12-month PFS rate was 86.8% (95% CI, 79.8%–91.6%) in the selpercatinib group and 65.7% (95% CI, 51.9%–76.4%) in the control group.
The overall response rate was 69.4% (95% CI, 62.4%–75.8%) in the selpercatinib group and 38.8% (95% CI, 29.1%–49.2%) in the control group.
Adverse events led to a dose reduction in 38.9% of patients in the selpercatinib group and 77.3% of patients in the control group. Adverse events led to treatment discontinuation in 4.7% of patients in the selpercatinib group and 26.8% of patients in the control group.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Pralsetinib is an oral RET-targeted therapy. In December 2020, the FDA approved pralsetinib for patients aged 12 years and older and for adults with advanced or metastatic RET-altered medullary thyroid cancer (MTC) or RET fusion–positive RAI-refractory differentiated thyroid cancer.
Evidence (pralsetinib):
A phase I/II, multicenter, open-label study (ARROW [NCT03037385]) evaluated the efficacy and safety of pralsetinib.[38]
A phase I/II, multicenter, open-label study (ARROW [NCT03037385]) evaluated the efficacy and safety of pralsetinib.[38]
At data cutoff, 147 patients had RET-altered MTC and 22 patients had RET fusion–positive differentiated thyroid cancer. A total of 142 patients with RET-altered MTC or RET fusion–positive differentiated thyroid cancer initiated the phase II dose of pralsetinib at 400 mg once daily.
There were 61 patients with RET-altered MTC who had previously received cabozantinib, vandetanib, or both, and 23 patients were treatment-naïve.
In patients with RET fusion–positive differentiated thyroid cancer, the overall response rate was 89% (95% CI, 52%–100%), all of which were partial responses. Duration of response was not reached after a median follow-up of 9.5 months. Median PFS was not reached (95% CI, NE), with an estimated 1-year PFS rate of 81% after a median follow-up of 12.9 months. Median OS was also not reached, with an estimated 1-year OS rate of 91% (95% CI, 74%–100%) after a median follow-up of 15.8 months.
The most frequent all-cause adverse events were anemia (45%), musculoskeletal pain (45%), constipation (44%), increased AST (42%), and hypertension (40%). Grade 3 to 4 treatment-related adverse events included hypertension (17%), neutropenia (13%), lymphopenia (12%), and anemia (10%). Serious adverse events were reported in 15% of patients; the most frequently reported serious adverse event was pneumonitis (4%).
Of note, in patients with RET-altered MTC previously treated with cabozantinib, vandetanib, or both, the overall response rate was 60% (95% CI, 46%–73%). One patient (2%) had a complete response. However, in 2023 pralsetinib was withdrawn from FDA approval for this indication.[39]
Sources: 39
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Larotrectinib is a potent and highly selective small-molecule inhibitor of the TRKA, TRKB, and TRKC proteins.
Evidence (larotrectinib):
An expanded pooled efficacy analysis included 159 patients with TRK fusion−positive cancers treated with larotrectinib. The safety analysis included 260 patients treated with larotrectinib, regardless of TRK gene fusion status.[40]
Sources: 40
An expanded pooled efficacy analysis included 159 patients with TRK fusion−positive cancers treated with larotrectinib. The safety analysis included 260 patients treated with larotrectinib, regardless of TRK gene fusion status.[40]
For the 24 patients with thyroid cancer, the overall response rate was 79% (95% CI, 58%−93%). The median duration of response was NE (14.8 months−NE).[40][Level of evidence C2]
Sources: 40 · Level of evidence C2
Of the 260 patients in the safety analysis, 13% had grade 3 treatment-related adverse events and less than 1% had grade 4 treatment-related adverse events.
An expanded pooled efficacy analysis included 159 patients with TRK fusion−positive cancers treated with larotrectinib. The safety analysis included 260 patients treated with larotrectinib, regardless of TRK gene fusion status.[40] › Of the 260 patients in the safety analysis, 13% had grade 3 treatment-related adverse events and less than 1% had grade 4 treatment-related adverse events.
The most common grade 3 or 4 treatment-related adverse events were increased alanine aminotransferase (3%), anemia (2%), and decreased neutrophil count (2%).
Doses were reduced in 8% of patients with TRK fusion–positive cancer because of adverse events. The drug was discontinued in 2% of patients because of treatment-related adverse events.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Entrectinib is a potent small-molecule inhibitor of the TRKA, TRKB, TRKC, ROS1, and ALK proteins.
Evidence (entrectinib):
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
Sources: 41
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41]
The objective response rate was 57% (95% CI, 34.2%−70.8%). Seven percent of patients had a complete response, and 50% of patients had a partial response.[41][Level of evidence C2]
Sources: 41 · Level of evidence C2
The median duration of response was 10 months (95% CI, 7.1−NE), and the median PFS was 11 months (95% CI, 8−14.9).
For the five patients with thyroid cancer, the overall response rate was 20% (95% CI, 1%−72%).
In the overall safety population (n = 355), the most frequently reported treatment-related adverse events were dysgeusia (41%), fatigue (28%), dizziness (26%), constipation (23%), and diarrhea (22%).
A pooled analysis of three phase I/II trials evaluated the efficacy and safety of entrectinib in patients with metastatic or locally advanced or unresectable NTRK fusion−positive solid tumors. The efficacy analysis included 54 adult patients with advanced or metastatic NTRK fusion−positive solid tumors.[41] › In the overall safety population (n = 355), the most frequently reported treatment-related adverse events were dysgeusia (41%), fatigue (28%), dizziness (26%), constipation (23%), and diarrhea (22%).
The most common grade 3 or 4 treatment-related adverse events were increased weight (5%) and anemia (5%).
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
EBRT or intraoperative radiation therapy can be useful in controlling symptoms related to local tumor recurrences.[42]
Sources: 42
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Patients with recurrent papillary or follicular thyroid cancer should consider enrolling in clinical trials evaluating new treatment approaches to this disease. Oral inhibitors targeting specific single nucleotide variants are under clinical evaluation, as are new immunotherapy approaches.[27-29][Level of evidence B4]
Sources: 27 · 29 · Level of evidence B4
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment options for localized MTC include:
Total thyroidectomy.
Sources: Total thyroidectomy
External-beam radiation therapy (EBRT).
Radioactive iodine is not used in the treatment of patients with MTC.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Patients with MTC are treated with total thyroidectomy unless there is evidence of distant metastasis. In patients with clinically palpable MTC, the incidence of microscopically positive nodes is more than 75%. Routine central and bilateral modified neck dissections are generally done.[9] When cancer is confined to the thyroid gland, the prognosis is excellent.
Sources: 9
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
EBRT has been used for palliation of locally recurrent tumors without evidence that it provides any survival advantage.[10]
Sources: 10
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment options for locally advanced and metastatic MTC include:
Targeted therapy.
Sources: Targeted therapy
RET kinase inhibitors.
Sources: RET kinase inhibitors
Palliative chemotherapy.
Sources: Palliative chemotherapy
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Vandetanib is an oral inhibitor of rearranged during transfection (RET) receptor kinase, vascular endothelial growth factor receptor (VEGFR), and epidermal growth-factor receptor.
Evidence (vandetanib):
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
Sources: NCT00410761 · 11 · Level of evidence B1
A placebo-controlled prospective trial (NCT00410761) evaluated vandetanib in 331 patients with locally advanced or metastatic disease. Patients were randomly assigned in a 2:1 ratio to receive vandetanib or placebo.[11][Level of evidence B1]
With a median follow-up of 24 months, progression-free survival (PFS) favored vandetanib (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.31–0.69; P < .001), with a median PFS estimated at 30.5 months for vandetanib versus 19.3 months for placebo.
OS was not different at 24 months. Longer follow-up will be required because all but 47 patients were alive at the time of analysis, and there was a crossover to the study drug on progression from placebo, making analysis of OS problematic.
Vandetanib treatment produces significant side effects, including diarrhea, rash, hypertension, and QT prolongation. Quality of life was not formally assessed in this trial.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Cabozantinib is an oral tyrosine kinase inhibitor of RET receptor kinase, hepatocyte growth factor receptor MET, and VEGFR-2.
Evidence (cabozantinib):
Cabozantinib was evaluated in a randomized, double-blind, placebo-controlled, phase III trial (EXAM [NCT00704730]). The study included 330 patients with metastatic MTC and radiographic progression of disease. Patients were randomly assigned in a 2:1 ratio to receive cabozantinib (140 mg per day) or placebo. Patients who received placebo were not permitted to cross over to cabozantinib. The primary end point was PFS. Additional outcomes included response rate, OS, and safety.[12][Level of evidence B1]
Sources: EXAM · 12 · Level of evidence B1
Cabozantinib was evaluated in a randomized, double-blind, placebo-controlled, phase III trial (EXAM [NCT00704730]). The study included 330 patients with metastatic MTC and radiographic progression of disease. Patients were randomly assigned in a 2:1 ratio to receive cabozantinib (140 mg per day) or placebo. Patients who received placebo were not permitted to cross over to cabozantinib. The primary end point was PFS. Additional outcomes included response rate, OS, and safety.[12][Level of evidence B1]
The estimated median PFS was 11.2 months in the cabozantinib group and 4.0 months in the placebo group (HR, 0.28; 95% CI, 0.19‒0.40; P < .001). A difference in PFS was observed across all subgroups and was independent of previous tyrosine kinase inhibitor treatment and RET pathogenic variant status.
During a planned interim analysis of OS, no statistically significant difference was observed between the two groups (HR, 0.98; 95% CI, 0.63‒1.52).
The objective response rate was 28% in the cabozantinib group (all partial responses) and 0% in the placebo group (P < .001). The median estimated duration of response was 14.6 months (95% CI, 11.1‒17.5 months). Responses were observed regardless of RET pathogenic variant status.
The most common cabozantinib-associated adverse events (all grades) included diarrhea (63.1%), palmar-plantar erythrodysesthesia (50%), decreased weight (47.7%), decreased appetite (45.8%), nausea (43%), and fatigue (40.7%)
Grade 3 or 4 adverse events were reported in 69% of patients in the cabozantinib group and 33% of patients in the placebo group.
Adverse events resulted in treatment discontinuation in 16% of patients who received cabozantinib and in 8% of patients who received placebo.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Selpercatinib is an orally active, highly selective, small-molecule RET kinase inhibitor.
Evidence (selpercatinib):
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13]
Sources: LIBRETTO-001 · 13
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13]
For patients with RET-altered MTC who were previously treated with vandetanib or cabozantinib:
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13] › For patients with RET-altered MTC who were previously treated with vandetanib or cabozantinib:
The objective response rate was 69% (95% CI, 55%−81%); 9% of patients had a complete response, and 60% of patients had a partial response.
At 1 year, 86% of responses were ongoing (95% CI, 67%−95%), and 100% of patients were progression-free.
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13]
For patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib:
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13] › For patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib:
The objective response rate was 73% (95% CI, 62%−82%); 11% of patients had a complete response, and 61% of patients had a partial response.[13][Level of evidence C2]
Sources: 13 · Level of evidence C2
At 1 year, 91% of responses were ongoing (95% CI, 72%−97%), and 92% of patients were progression-free.
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13]
Treatment-related adverse events (any grade) occurred in 94% of patients.
A phase I/II trial (LIBRETTO-001 [NCT03157128]) evaluated the safety and efficacy of selpercatinib in adolescent and adult patients with any solid tumor type harboring an activating RET alteration. The primary end point was an objective response (complete response or partial response). The trial enrolled 55 patients with RET-altered MTC who were previously treated with vandetanib, cabozantinib, or both; and 88 patients with RET-altered MTC who were not previously treated with vandetanib or cabozantinib. Eighty two percent of previously treated patients received the recommended phase II dose of 160 mg twice daily, and 98% of previously untreated patients received 160 mg twice daily.[13] › Treatment-related adverse events (any grade) occurred in 94% of patients.
Grade 3 adverse events were observed in 28% of patients, and grade 4 adverse events were observed in 2% of patients.
The most frequent adverse events were dry mouth (46%), hypertension (43%), diarrhea (38%), fatigue (38%), increased aspartate aminotransferase level (35%), nausea (35%), and constipation (35%).
Thirty percent of patients had dose reductions because of treatment-related adverse events, and 2% of patients discontinued the drug because of adverse events.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Palliative chemotherapy has been reported to produce occasional responses in patients with metastatic disease.[14-17] No single drug regimen can be considered standard. Some patients with distant metastases will experience prolonged survival and can be managed expectantly until they become symptomatic.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Treatment options for anaplastic thyroid cancer include:
Surgery.
Sources: Surgery
External-beam radiation therapy (EBRT).
Systemic therapy.
Sources: Systemic therapy
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
EBRT may be used in patients who are not surgical candidates or whose tumor cannot be surgically excised.
Source: Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 9, 2025. Captured 2026-09-09.
Anaplastic thyroid cancer is not responsive to iodine I 131 therapy. Treatment with individual anticancer drugs has been reported to produce partial remissions in some patients. Approximately 30% of patients achieve a partial remission with doxorubicin.[4] The combination of doxorubicin plus cisplatin appears to be more active than doxorubicin alone and has produced more complete responses.[5]
The combination of chemotherapy plus radiation therapy after complete resection may provide prolonged survival in some patients, but this treatment combination has not been compared with any one modality alone.[6,7]
An estimated 25% of patients with anaplastic thyroid cancers have an activating BRAF V600E variant.[8]
Sources: 8
Evidence (dabrafenib and trametinib):
A phase II trial of BRAF and MEK inhibitors, dabrafenib and trametinib, included 16 patients with anaplastic thyroid cancer and a BRAF V600E variant.[9][Level of evidence C2]
Sources: 9 · Level of evidence C2
A phase II trial of BRAF and MEK inhibitors, dabrafenib and trametinib, included 16 patients with anaplastic thyroid cancer and a BRAF V600E variant.[9][Level of evidence C2]
The confirmed overall response rate was 69%. The median duration of response, progression-free survival (PFS), and overall survival (OS) were not reached.
Twelve-month estimates were 90% for duration of response, 79% for PFS, and 80% for OS.
Based on this data, the U.S. Food and Drug Administration approved the combination of dabrafenib and trametinib for the treatment of unresectable or metastatic anaplastic thyroid cancer with a BRAF V600E variant. Molecular testing for the BRAF V600E variant is advised for patients with anaplastic thyroid cancer.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on the following:
Sources: prognosis
The age of the patient at the time of diagnosis.
The type of thyroid cancer.
The stage of the cancer.
Sources: stage
Whether the cancer was completely removed by surgery.
Whether the patient has multiple endocrine neoplasia type 2B (MEN 2B).
The patient's general health.
Whether the cancer has just been diagnosed or has recurred (come back).
Sources: recurred
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
The cancer may come back in the thyroid or in other parts of the body.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
There are different types of treatment for patients with thyroid cancer.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Radiation therapy, including radioactive iodine therapy
Chemotherapy
Thyroid hormone therapy
Targeted therapy
Watchful waiting
New types of treatment are being tested in clinical trials.
New types of treatment are being tested in clinical trials.
Immunotherapy
Treatment for thyroid cancer may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up tests may be needed.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with thyroid cancer. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: thyroid cancer · standard · clinical trials · research study · cancer
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Surgery is the most common treatment for thyroid cancer. One of the following procedures may be used:
Sources: Surgery
Lobectomy: Removal of the lobe in which thyroid cancer is found. Lymph nodes near the cancer may also be removed and checked under a microscope for signs of cancer.
Sources: Lobectomy · lobe · Lymph nodes · microscope
Near-total thyroidectomy: Removal of all but a very small part of the thyroid. Lymph nodes near the cancer may also be removed and checked under a microscope for signs of cancer.
Sources: thyroidectomy · thyroid
Total thyroidectomy: Removal of the whole thyroid. Lymph nodes near the cancer may also be removed and checked under a microscope for signs of cancer.
Tracheostomy: Surgery to create an opening (stoma) into the windpipe to help you breathe. The opening itself may also be called a tracheostomy.
Sources: Tracheostomy · stoma · windpipe
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
Sources: Radiation therapy · x-rays · radiation · cells
External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Sometimes the radiation is aimed directly at the tumor during surgery. This is called intraoperative radiation therapy.
Sources: External radiation therapy · tumor · intraoperative radiation therapy
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.
Sources: Internal radiation therapy · radioactive · seeds · catheters
Radiation therapy may be given after surgery to kill any thyroid cancer cells that were not removed. Follicular and papillary thyroid cancers are sometimes treated with radioactive iodine (RAI) therapy. RAI is taken by mouth and collects in any remaining thyroid tissue, including thyroid cancer cells that have spread to other places in the body. Since only thyroid tissue takes up iodine, the RAI destroys thyroid tissue and thyroid cancer cells without harming other tissue. Before a full treatment dose of RAI is given, a small test-dose is given to see if the tumor takes up the iodine.
Sources: Follicular · papillary thyroid cancers · radioactive iodine · tissue · iodine · dose
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External radiation therapy and radioactive iodine (RAI) therapy are used to treat thyroid cancer.
Sources: stage
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). When chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a body cavity such as the abdomen, the drugs mainly affect cancer cells in those areas (regional chemotherapy).
Sources: Chemotherapy · drugs · injected · vein · systemic chemotherapy · cerebrospinal fluid · organ · cavity · abdomen · regional chemotherapy
The way the chemotherapy is given depends on the type and stage of the cancer being treated.
See Drugs Approved for Thyroid Cancer for more information.
Sources: Drugs Approved for Thyroid Cancer
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances made by glands in the body and circulated in the bloodstream. In the treatment of thyroid cancer, drugs may be given to prevent the body from making thyroid-stimulating hormone (TSH), a hormone that can increase the chance that thyroid cancer will grow or recur.
Sources: Hormone therapy · hormones · glands · thyroid-stimulating hormone · recur
Also, because thyroid cancer treatment kills thyroid cells, the thyroid is not able to make enough thyroid hormone. Patients are given thyroid hormone replacement pills.
Sources: thyroid hormone · thyroid hormone replacement
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells. There are different types of targeted therapy:
Sources: Targeted therapy
Tyrosine kinase inhibitor. Tyrosine kinase inhibitor therapy blocks signals needed for tumors to grow. Sorafenib, lenvatinib, vandetanib, cabozantinib, selpercatinib, larotrectinib, entrectinib, and pralsetinib are used to treat certain types of thyroid cancer. New types of tyrosine kinase inhibitors are being studied to treat advanced thyroid cancer.
Sources: Tyrosine kinase inhibitor · Sorafenib · lenvatinib · vandetanib · cabozantinib · selpercatinib · larotrectinib · entrectinib · pralsetinib · advanced
Protein kinase inhibitor. Protein kinase inhibitor therapy blocks proteins needed for cell growth and may kill cancer cells. Dabrafenib and trametinib are used to treat anaplastic thyroid cancer in patients with a certain mutation in the BRAF gene.
Sources: Protein kinase inhibitor · proteins · Dabrafenib · trametinib · anaplastic thyroid cancer · mutation · BRAF · gene
See Drugs Approved for Thyroid Cancer for more information.
Sources: Drugs Approved for Thyroid Cancer
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change.
Sources: Watchful waiting · monitoring · condition · signs · symptoms
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Immunotherapy is a treatment that uses the patient’s immune system to fight cancer. Substances made by the body or made in a laboratory are used to boost, direct, or restore the body’s natural defenses against cancer. This cancer treatment is a type of biologic therapy. Immunotherapy is being studied as a treatment for thyroid cancer.
Sources: Immunotherapy · immune system · biologic therapy
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of stage I (younger than 55 years; 55 years and older), stage II (younger than 55 years; 55 years and older), and stage III papillary and follicular thyroid cancer may include the following:
Sources: younger than 55 years · 55 years and older · younger than 55 years · 55 years and older · stage III papillary and follicular thyroid cancer
Surgery (thyroidectomy or lobectomy).
Sources: Surgery · thyroidectomy · lobectomy
Radioactive iodine therapy.
Sources: Radioactive iodine · therapy
Hormone therapy to prevent the body from making thyroid-stimulating hormone (TSH).
Sources: Hormone therapy · thyroid-stimulating hormone
External radiation therapy.
Sources: External radiation therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
When cancer has spread to other places in the body, such as the lungs and bone, treatment usually does not cure the cancer, but can relieve symptoms and improve the quality of life. Treatment of stage IV papillary and follicular thyroid cancer may include the following:
Sources: cancer · lungs · symptoms · quality of life · stage IV papillary and follicular thyroid cancer
For tumors that take up iodine
Total thyroidectomy.
Sources: thyroidectomy
Radioactive iodine therapy.
Sources: Radioactive iodine · therapy
Hormone therapy to prevent the body from making thyroid-stimulating hormone (TSH).
Sources: Hormone therapy · thyroid-stimulating hormone
For tumors that do not take up iodine
Total thyroidectomy.
Sources: thyroidectomy
Hormone therapy to prevent the body from making thyroid-stimulating hormone (TSH).
Sources: Hormone therapy · thyroid-stimulating hormone
Targeted therapy with a tyrosine kinase inhibitor (sorafenib or lenvatinib).
Sources: Targeted therapy · tyrosine kinase inhibitor · sorafenib · lenvatinib
Surgery to remove cancer from areas where it has spread.
Sources: Surgery
External-beam radiation therapy.
Sources: External-beam radiation therapy
A clinical trial of chemotherapy.
Sources: clinical trial · chemotherapy
A clinical trial of a targeted therapy.
Sources: targeted therapy
A clinical trial of immunotherapy.
Sources: immunotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of recurrent papillary and follicular thyroid cancer may include the following:
Sources: recurrent · papillary · follicular thyroid cancer
Surgery to remove the tumor with or without radioactive iodine therapy.
Sources: Surgery · tumor · radioactive iodine · therapy
Radioactive iodine therapy when the cancer can be found only by a thyroid scan and cannot be felt during a physical exam.
Sources: cancer · thyroid · scan · physical exam
Targeted therapy with a tyrosine kinase inhibitor (sorafenib, lenvatinib, cabozantinib, selpercatinib, pralsetinib, larotrectinib, or entrectinib).
Sources: Targeted therapy · tyrosine kinase inhibitor · sorafenib · lenvatinib · cabozantinib · selpercatinib · pralsetinib · larotrectinib · entrectinib
External radiation therapy or intraoperative radiation therapy as palliative therapy to relieve symptoms and improve thequality of life.
Sources: External radiation therapy · intraoperative radiation therapy · palliative therapy · symptoms · quality of life
Chemotherapy.
A clinical trial of a targeted therapy.
Sources: clinical trial · targeted therapy
A clinical trial of immunotherapy.
Sources: immunotherapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Localized medullary thyroid cancer is in the thyroid only and may have spread to nearby muscles in the neck. Locally advanced and metastatic thyroid cancer has spread to other parts of the neck or to other parts of the body.
Sources: Localized · medullary thyroid cancer · thyroid · Locally advanced · metastatic
Treatment of localized medullary thyroid cancer may include the following:
Total thyroidectomy if the cancer has not spread to other parts of the body.Lymph nodes near the cancer are also removed.
Sources: thyroidectomy · cancer · Lymph nodes
External radiation therapy for patients whose cancer has recurred in the thyroid.
Sources: External radiation therapy · recurred · thyroid
Treatment of locally advanced/metastatic medullary thyroid cancer may include the following:
Targeted therapy with a tyrosine kinase inhibitor (vandetanib, cabozantinib, or selpercatinib) for cancer that has spread to other parts of the body.
Sources: Targeted therapy · tyrosine kinase inhibitor · vandetanib · cabozantinib · selpercatinib
Chemotherapy as palliative therapy to relieve symptoms and improve the quality of life for patients whose cancer has spread to other parts of the body.
Sources: Chemotherapy · palliative therapy · symptoms · quality of life
Radioactive iodine therapy is not used to treat medullary thyroid cancer.
Sources: Radioactive iodine · therapy
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Thyroid Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 12, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Treatment of anaplastic thyroid cancer may include the following:
Total thyroidectomy as palliative therapy to relieve symptoms and improve the quality of life for patients whose cancer is in or near the thyroid.
Sources: thyroidectomy · palliative therapy · symptoms · quality of life · cancer · thyroid
Tracheostomy as palliative therapy to relieve symptoms and improve the quality of life.
Sources: Tracheostomy
External radiation therapy.
Sources: External radiation therapy
Chemotherapy.
Sources: Chemotherapy
Targeted therapy with protein kinase inhibitors (dabrafenib and trametinib) for patients with a certain mutation in the BRAF gene.
Sources: Targeted therapy · protein kinase inhibitors · dabrafenib · trametinib · mutation · BRAF · gene
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Thyroid Cancer
ClinicalTrials.gov recordThyroid Cancer
ClinicalTrials.gov recordThyroid Neoplasms
ClinicalTrials.gov recordThyroid Cancer
ClinicalTrials.gov recordTumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC)
ClinicalTrials.gov recordRET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm,...
ClinicalTrials.gov recordNon-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
ClinicalTrials.gov recordDifferentiated Thyroid Cancer
ClinicalTrials.gov recordMedullary Thyroid Cancer
ClinicalTrials.gov recordThyroid Neoplasms, Goiter, Nodular, Thyroid Nodule, Graves' Disease, Hyperparathyroidism
ClinicalTrials.gov recordPostoperative Hypoparathyroidism, Thyroid Neoplasms, Thyroid Cancer
ClinicalTrials.gov recordNeoplasms, Colorectal Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma,...
ClinicalTrials.gov recordPostoperative Hypoparathyroidism, Thyroid Disease, Thyroid Neoplasms, Thyroid Cancer
ClinicalTrials.gov record1 INDICATIONS AND USAGE CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.
COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
1.1 Differentiated Thyroid Cancer LENVIMA is indicated for the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).
Localized/regional papillary and follicular thyroid cancer
1.4 BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer...
Metastatic papillary and follicular thyroid cancer
1.3 Differentiated Thyroid Carcinoma NEXAVAR is indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.
Recurrent papillary and follicular thyroid cancer
Treatment of Stage IV Papillary and Follicular Thyroid Cancer (Metastatic)
1.5 BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer...
1.2 Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer THYROGEN is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or...
Thyroid Cancer
CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly...
DailyMed labelCOMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid...
DailyMed labelCYTOMEL is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary...
DailyMed labelEUTHYROX is L-thyroxine (T4) indicated in pediatric and adult patients for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelHICON ® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. HICON ® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed label1 INDICATION AND USAGE Levothyroxine Sodium capsules are L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelINDICATIONS AND USAGE Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during...
DailyMed labelHypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. () • Pituitary...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelLevothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) •...
DailyMed labelHypothyroidism Levothyroxine Sodium Tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired...
DailyMed labelLEVOXYL is L-thyroxine (T4) indicated in pediatric and adult patients for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) Pituitary...
DailyMed labelLiothyronine sodium is an L-triiodothyronine (T3) indicated for: • Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) • Pituitary...
DailyMed labelNEXAVAR is a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC)...
DailyMed labelRETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an...
DailyMed labelHypothyroidism SYNTHROID is indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism....
DailyMed labelHypothyroidism THYQUIDITY is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH)...
DailyMed labelTHYROGEN ® is a thyroid stimulating hormone indicated for: Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging...
DailyMed label1 INDICATION AND USAGE TIROSINT is L-thyroxine (T4) indicated for adults and pediatric patients 6 years and older with: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic)...
DailyMed label1 INDICATION AND USAGE TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary...
DailyMed labelHypothyroidism UNITHROID is indicated in pediatric and adult patients as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin...
DailyMed label